4Mauvais JF, Sobngwi E, Porcher R, et al. Ketosis-prnne type2 diabetes in patients of Sub-Saharan origin : clinical pathophysiology and nayural history of beta-cell dysfunction and insulin resistance [ J ]. Diabetes ,2004,53 ( 11 ) :645-653.
5Maldonado M, Hampe CS, Gaur LK, et at. Ketosis-prone diabetes; dissection of a heterogeneous syndrome using an immunogentic and B-cell functional lassification, prospective analysis, and clinical outcomes[J]. J Clin Endocrinol Metab,2002,88(3):5090-5098.
6南京市卫生局.医药科技进展.北京:中国医药科技出版社,2008;326:341-348.
7Purreio F,Rabuazza AM.Metabolic factors that effect beta cell function and survival.Diabetes Nutr Metab,2000,13(2):8492.
8UK Prospective Diabetes Study(UKPDS)Group.Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)[J].Lancet,1998,352(9131):837-853.
9Stratton IM,Adler AI,Neil HA,et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study[J].BMJ,2000,321 (7258):405-412.
10Skyler JS,Bergenstal R,Bonow RO,et al.Intensive glycernic control and the prevention of cardiovascular events:implications of the ACCORD,ADVANCE,and VA Diabetes Trials:a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Hearl Association[J].J Am Coil Cardiol,2009,53(3): 298-304.
